You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.
The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.
Dante Labs will use library preparation kits from Nonacus and software from CCG.ai to create a sample-to-report service, the firms said.
The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.
The company's software-related revenues grew year over year, but its sequencing and molecular analysis revenues declined.